Where the application of ribonucleic acid (RNA) in medicine is concerned, two companies have so far led the way.
The antisense technology of Ionis Pharmaceuticals (Nasdaq: IONS), founded in 1989, and the RNA interference therapeutics of 19-year-old company Alnylam Pharmaceuticals (Nasdaq: ALNY) have shown the broader potential of the space.
Their progress raises the question of which company will be the next RNA pioneer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze